FLASCO

 

Corporate Members

Diamond Elite

Diamond

Platinum

Gold

Silver

Latest News

Upcoming Changes to Genentech Patient Foundation Enrollment Forms

As part of Genentech’s ongoing commitment to patient access and ensuring that patients and practices have a positive experience with Genentech, we constantly assess our processes to ensure they remain in the best interest of our practices and patients. Starting October 21st 2019, we will be launching a faster, more intuitive Genentech Patient Foundation enrollment...

Alexion Receives FDA Approval For ULTOMIRIS® (Ravulizumab-Cwvz) For Atypical Hemolytic Uremic Syndrome (AHUS)

October 18, 2019 at 7:45 PM EDT PDF Version – At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response – BOSTON–(BUSINESS WIRE)–Oct. 18, 2019– Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food and Drug Administration (FDA) approved ULTOMIRIS® (ravulizumab-cwvz) for the treatment of atypical hemolytic uremic syndrome (aHUS)...

Genentech Access Solutions – Medicare Beneficiary Identifier (MBI) Update

Genentech Access Solutions – Medicare Beneficiary Identifier (MBI) Update This PDF provides important information about The Centers for Medicare & Medicaid (CMS) transition from the use of the Health Insurance Claim Number (HICN) to a Medicare Beneficiary Identifier (MBI) number, and how Genentech Access Solutions is addressing this conversion. Beginning January 1, 2020, Genentech Access...

Radon Education

Radon, is the number one leading cause of lung cancer among non-smokers in the U.S. Radon is a colorless, odorless, and tasteless gas that you would have no way of knowing you were being exposed to.

Who’s Online

There are no users currently online